NTLA-2002

Technology

Last mentioned: Feb 26, 2026

Timeline

Feb 26, 2026
Functional Cure Declared

Medical reports confirm the patient is effectively cured of the rare disease.
Jun 10, 2025
Long-term Follow-up

B.C. patient reports zero attacks one year after single dose.
Mar 15, 2024
Phase 1/2 Results

Intellia releases early data showing significant reduction in HAE attacks.

Stories mentioning NTLA-2002 1

B.C. Man Cured of Rare Disease in Landmark CRISPR Gene-Editing Success

A British Columbia man has been declared functionally cured of Hereditary Angioedema (HAE) following a world-first in-vivo CRISPR gene-editing treatment. The success of Intellia Therapeutics' NTLA-2002 therapy marks a pivotal shift from chronic disease management to permanent genetic correction.

Feb 26, 2026 2 sources